Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)

NCT00813332 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Advanced NSCLC
Recurrent NSCLC

Interventions

DRUG: Endostar(rh recombinant endostatin) plus Docetaxel
DRUG: Placebo plus Docetaxel

Sponsor

Simcere Pharmaceutical Co., Ltd